低剂量计划型葡萄糖酶允许对中枢神经系统淋巴瘤进行安全的门诊高剂量甲索特治疗
Lauren R Schaff1,2, Dean Carlow3, Ryan Schofield3
1Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY.
JCO oncology practice
|June 25, 2024
概括
对于中枢神经系统淋巴瘤的门诊高剂量甲状腺素 (HD-MTX) 是可行的. 这种方法是安全的,耐受性很好,可以避免住院治疗,从而有可能改善患者的生活质量.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 高剂量甲状腺素 (HD-MTX) 是用于中枢神经系统 (CNS) 淋巴瘤的标准治愈疗法.
- 由于毒性和监测要求,目前HD-MTX的住院治疗需要长时间住院 (3-5天).
- 这些住院导致患者负担很大,包括远离工作和家的时间,以及暴露于医院感染.
研究的目的:
- 评估在门诊环境中使用HD-MTX的可行性和安全性.
- 评估低剂量葡萄糖酶在促进门诊治疗MTX清除方面的疗效.
- 为中枢神经系统淋巴瘤患者证明HD-MTX在住院治疗中的潜在替代品.
主要方法:
- 一项前性,非随机化研究 (NCT03684980) 涉及中枢神经系统淋巴瘤和充分功能患者.
- 患者在输液后24小时接受了门诊的HD-MTX (3.5g/m2),随后接受了葡萄糖酶 (2000单位).
- 主要终点是HD-MTX给药后48小时的MTX水平评估.
主要成果:
- 给七名患者服用了门诊HD-MTX与葡萄糖酶的20剂.
- 所有的治疗 (100%) 导致血清MTX水平在48小时内低于100nmol/L.
- 治疗耐受性很好,不需要住院治疗,罕见地产生抗葡萄糖酶抗体.
结论:
- 通过葡萄糖酶促进的门诊HD-MTX管理是中枢神经系统淋巴瘤的安全和耐受性良好的治疗选择.
- 这种门诊方法有可能显著改变中枢神经系统淋巴瘤的护理标准.
- 研究结果表明,与传统的住院治疗方案相比,改善了患者的便利性和减少了医疗保健负担.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
780
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
780
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
703
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
703